英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

eikon    
n. 圣像;画像;肖像;插画;图

圣像;画像;肖像;插画;图


请选择你想看的字典辞典:
单词字典翻译
Eikon查看 Eikon 在百度字典中的解释百度英翻中〔查看〕
Eikon查看 Eikon 在Google字典中的解释Google英翻中〔查看〕
Eikon查看 Eikon 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Eikon Therapeutics
    Eikon is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs We are passionate about novel therapeutics and share the belief that a better understanding of fundamental human disease biology can lead to better medicines
  • Refinitiv Eikon
    All the information you need to install and to download Refinitiv Eikon Direct link to test if your system can run Refinitiv Eikon
  • Eikon Therapeutics, Inc. (EIKN) - Yahoo Finance
    Find the latest Eikon Therapeutics, Inc (EIKN) stock quote, history, news and other vital information to help you with your stock trading and investing
  • Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 . . .
    --Eikon Therapeutics, Inc , a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and
  • Eikon Therapeutics (EIKN) Stock Price Overview
    A detailed overview of Eikon Therapeutics, Inc (EIKN) stock, including real-time price, chart, key statistics, news, and more
  • Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key . . .
    Eikon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results: Key Corporate and Clinical Developments IPO Success and Strengthened Financial Position Eikon Therapeutics, Inc (Nasdaq: EIKN), a late-stage clinical biopharmaceutical company focused on developing innovative cancer therapies, announced significant milestones in its fourth-quarter and full-year 2025 results Most
  • Eikon upsized $381M listing marks largest biotech IPO since 2024
    At $381 million, Eikon looks set to be the largest biotech IPO since 2024, overtaking Aktis Oncology’s $318 million offering last month The California-based company has already set out its plans
  • Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 . . .
    MILLBRAE, Calif , March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates
  • Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
    Eikon Therapeutics, a star-studded biotechnology startup that raised more than $1 billion in venture funding, said Wednesday it has secured $381 million more through an initial public offering
  • Eikon Therapeutics Completes Upsized IPO Raising $381 Million and . . .
    Eikon Therapeutics, Inc recently announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical programs and a successful upsized initial public offering that raised $381 million in February 2026





中文字典-英文字典  2005-2009